Research ArticlePerspectives in Pharmacology
Animal Models That Best Reproduce the Clinical Manifestations of Human Intoxication with Organophosphorus Compounds
Edna F. R. Pereira, Yasco Aracava, Louis J. DeTolla Jr., E. Jeffrey Beecham, G. William Basinger Jr., Edgar J. Wakayama and Edson X. Albuquerque
Journal of Pharmacology and Experimental Therapeutics August 2014, 350 (2) 313-321; DOI: https://doi.org/10.1124/jpet.114.214932
Edna F. R. Pereira
Division of Translational Toxicology, Department of Epidemiology and Public Health (E.F.R.P., Y.A., E.X.A.), and Program of Comparative Medicine and Departments of Pathology, Medicine, and Epidemiology and Public Health (L.J.D.), University of Maryland School of Medicine, Baltimore, Maryland; Countervail Corporation, Charlotte, North Carolina (E.J.B., G.W.B.); and Biomedical Advanced Research and Development Authority and Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC (E.J.W.)
Yasco Aracava
Division of Translational Toxicology, Department of Epidemiology and Public Health (E.F.R.P., Y.A., E.X.A.), and Program of Comparative Medicine and Departments of Pathology, Medicine, and Epidemiology and Public Health (L.J.D.), University of Maryland School of Medicine, Baltimore, Maryland; Countervail Corporation, Charlotte, North Carolina (E.J.B., G.W.B.); and Biomedical Advanced Research and Development Authority and Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC (E.J.W.)
Louis J. DeTolla Jr.
Division of Translational Toxicology, Department of Epidemiology and Public Health (E.F.R.P., Y.A., E.X.A.), and Program of Comparative Medicine and Departments of Pathology, Medicine, and Epidemiology and Public Health (L.J.D.), University of Maryland School of Medicine, Baltimore, Maryland; Countervail Corporation, Charlotte, North Carolina (E.J.B., G.W.B.); and Biomedical Advanced Research and Development Authority and Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC (E.J.W.)
E. Jeffrey Beecham
Division of Translational Toxicology, Department of Epidemiology and Public Health (E.F.R.P., Y.A., E.X.A.), and Program of Comparative Medicine and Departments of Pathology, Medicine, and Epidemiology and Public Health (L.J.D.), University of Maryland School of Medicine, Baltimore, Maryland; Countervail Corporation, Charlotte, North Carolina (E.J.B., G.W.B.); and Biomedical Advanced Research and Development Authority and Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC (E.J.W.)
G. William Basinger Jr.
Division of Translational Toxicology, Department of Epidemiology and Public Health (E.F.R.P., Y.A., E.X.A.), and Program of Comparative Medicine and Departments of Pathology, Medicine, and Epidemiology and Public Health (L.J.D.), University of Maryland School of Medicine, Baltimore, Maryland; Countervail Corporation, Charlotte, North Carolina (E.J.B., G.W.B.); and Biomedical Advanced Research and Development Authority and Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC (E.J.W.)
Edgar J. Wakayama
Division of Translational Toxicology, Department of Epidemiology and Public Health (E.F.R.P., Y.A., E.X.A.), and Program of Comparative Medicine and Departments of Pathology, Medicine, and Epidemiology and Public Health (L.J.D.), University of Maryland School of Medicine, Baltimore, Maryland; Countervail Corporation, Charlotte, North Carolina (E.J.B., G.W.B.); and Biomedical Advanced Research and Development Authority and Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC (E.J.W.)
Edson X. Albuquerque
Division of Translational Toxicology, Department of Epidemiology and Public Health (E.F.R.P., Y.A., E.X.A.), and Program of Comparative Medicine and Departments of Pathology, Medicine, and Epidemiology and Public Health (L.J.D.), University of Maryland School of Medicine, Baltimore, Maryland; Countervail Corporation, Charlotte, North Carolina (E.J.B., G.W.B.); and Biomedical Advanced Research and Development Authority and Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC (E.J.W.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticlePerspectives in Pharmacology
Acute and Delayed Clinical Manifestations of OP Toxicity
Edna F. R. Pereira, Yasco Aracava, Louis J. DeTolla, E. Jeffrey Beecham, G. William Basinger, Edgar J. Wakayama and Edson X. Albuquerque
Journal of Pharmacology and Experimental Therapeutics August 1, 2014, 350 (2) 313-321; DOI: https://doi.org/10.1124/jpet.114.214932
Research ArticlePerspectives in Pharmacology
Acute and Delayed Clinical Manifestations of OP Toxicity
Edna F. R. Pereira, Yasco Aracava, Louis J. DeTolla, E. Jeffrey Beecham, G. William Basinger, Edgar J. Wakayama and Edson X. Albuquerque
Journal of Pharmacology and Experimental Therapeutics August 1, 2014, 350 (2) 313-321; DOI: https://doi.org/10.1124/jpet.114.214932
Jump to section
- Article
- Abstract
- Clinical Manifestations of Human Exposure to OP Compounds: Acute and Long-Term Clinical Signs and Symptoms
- Animal Models of OP Intoxication
- Molecular Mechanisms That Contribute to the Acute and Delayed Toxicity of OP Compounds
- Acknowledgments
- Authorship Contributions
- Footnotes
- Abbreviations
- References
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement